- 作者：Ignacio Zapardiel ; Piergiorgio Rosenberg ; Michele Peiretti ; Vanna Zanagnolo ; Fabio Sanguineti ; Giovanni Aletti ; Fabio L ; oni ; Luca Bocciolone ; Nicoletta Colombo ; Angelo Maggioni
- 关键词：Borderline ovarian tumor ; Restaging surgery ; Restaging procedure
- 刊名：Gynecologic Oncology
- 出版年：2010
- 出版时间：November 2010
- 年：2010
- 卷：119
- 期：2
- 页码：274-277
- 全文大小：152 K
BackgroundBorderline ovarian tumors (BOTs) are a histological category of epithelial ovarian tumors and 70 % of them are early diagnosed (stage I). Since early stage is the most important prognostic factor, restaging procedure could be justified. This study aims to evaluate the role of restaging surgery in the management of patients with borderline ovarian tumors referred to our Institution after being incompletely surgically staged in other hospitals.Materials and methods
We retrospectively reviewed the charts of patients with BOT who were referred to our centre to undergo restaging procedure. From December 1995 to May 2008, 186 patients were treated for BOT and 70 patients met the inclusion criteria. Data collected included patients' age, primary and re-staging surgery details, FIGO stage after first and second procedure, pathological findings, and follow-up data.
Results
FIGO stage after primary surgery was IA in 46 patients (68.6 % ), IB in 7 patients (10.4 % ), IC in 12 patients (17.9 % , 6 due to ruptured cyst), IIA in 1 patient (1.4 % ), IIB in 1 patient (1.4 % ), III B in 2 patients (2.8 % ), and IIIC in 1 patient (1.4 % ). Among stage I patients (representing 97 % of all patients), 12.3 % (8 patients) were up-staged. The upstaging rate among serous tumors was 16.2 % , and 4 % among mucinous tumors. The mean follow-up time was 60.4 months from restaging surgery (SD 30.6 months). We observed 8 primary recurrences of the disease and 3 second recurrences.
Conclusions
There were no differences in terms of overall survival between patients who were upstaged and those who were not. Restaging procedure does not seem to have a significant impact on the management of patients diagnosed with borderline ovarian tumors, especially in mucinous subtype and apparent FIGO stage higher than I.